We found that the expression levels of IC-related genes, such as HAVCR2, CD86, LAIR1, and VTCN1, in the high-risk group were significantly higher than those in the low-risk group, thereby explaining the higher sensitivity shown by the high-risk group to immunotherapy and confirming the high-risk group as a “hot tumor” group. This evidence concerns the gene CD86 and neoplasm.